In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 181-187

  Lehner, Martin D ^a   Marx, Degenhard ^a   Boer, Rainer ^a   Strub, Andreas ^a   Hesslinger, Christian ^a   Eltze, Manfrid ^a   Ulrich, Wolf Rüdiger ^a   Schwoebel, Frank ^a   Schermuly, Ralph Theo ^b   Barsig, Johannes ^a  

^a ALTANA PHARMA AG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [2 (4 METHOXY PYRIDIN 2 YL)ETHYL] 3H IMIDAZO [4,5 B]PYRIDINE; BYK 191023; IMIDAZOPYRIDINE DERIVATIVE; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPTIC SHOCK;

ANIMALS; BLOOD PRESSURE; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; HYPOTENSION; IMIDAZOLES; LIPOPOLYSACCHARIDES; MALE; NITRIC OXIDE SYNTHASE TYPE II; NITROGEN OXIDES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC;

EID: 33645114356     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.098673     Document Type: Article

References (39)

1. Alderton WK, Angell AD, Craig C, Dawson J, Garvey E, Moncada S, Monkhouse J, Rees D, Russell LJ, Russell RJ, et al. (2005) GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br J Pharmacol 145:301-312.
2. Alderton WK, Cooper CE, and Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357:593-615.
3. G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 32:1-12.
4. Beale RJ, Hollenberg SM, Vincent JL, and Parrillo JE (2004) Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 32:S455-S465.
5. Cai M, Sakamoto A, and Ogawa R (1996) Inhibition of nitric oxide formation with L-canavanine attenuates endotoxin-induced vascular hyporeactivity in the rat. Eur J Pharmacol 295:215-220.
6. Cheng X, Leung SW, Lo LS, and Pang CC (2003) Selective versus non-selective suppression of nitric oxide synthase on regional hemodynamics in rats with or without lipopolysaccharide-induced endotoxemia. Naunyn-Schmiedeberg's Arch Pharmacol 367:372-379.
7. Cobb JP (2001) Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg Infect (Larchmt) 2:93-100.
8. Cohen RI, Shapir Y, Davis A, Loona R, and Scharf SM (2000) Comparison between selective and nonselective nitric oxide synthase inhibition and phenylephrine in normal and endotoxic swine. Crit Care Med 28:3257-3267.
9. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di P, Serraino I, Britti D, Caputi AP, and Thiemermann C (2002) Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol 453:119-129.
10. Cuzzocrea S, Mazzon E, Dugo L, Barbera A, Centorrino T, Ciccolo A, Fonti MT, and Caputi AP (2001) Inducible nitric oxide synthase knockout mice exhibit resistance to the multiple organ failure induced by zymosan. Shock 16:51-58.
11. Dellinger RP and Parrillo JE (2004) Mediator modulation therapy of severe sepsis and septic shock: does it work? Crit Care Med 32:282-286.
12. Filep JG, Delalandre A, and Beauchamp M (1997) Dual role for nitric oxide in the regulation of plasma volume and albumin escape during endotoxin shock in conscious rats. Circ Res 81:840-847.
13. Gray GA, Schott C, Julou-Schaeffer G, Fleming I, Parratt JR, and Stoclet JC (1991) The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol 103:1218-1224.
14. Groeneveld AB, Bronsveld W, and Thijs LG (1986) Hemodynamic determinants of mortality in human septic shock. Surgery 99:140-153.
15. Hollenberg SM, Cunnion RE, and Zimmerberg J (1993) Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 264:H660-H663.
16. Ichinose F, Hataishi R, Wu JC, Kawai N, Rodrigues AC, Mallari C, Post JM, Parkinson JF, Picard MH, Bloch KD, et al. (2003) A selective inducible NOS dimerization inhibitor prevents systemic, cardiac and pulmonary hemodynamic dysfunction in endotoxemic mice. Am J Physiol 285:H2524-H2530.
17. Laubach VE, Shesely EG, Smithies O, and Sherman PA (1995) Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 92:10688-10692.
18. Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, and Feihl F (1998) Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock. J Infect Dis 177:127-132.
19. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al. (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21-30.
20. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, and Hutchinson N (1995) Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641-650.
21. Matejovic M, Krouzecky A, Martinkova V, Rokyta R Jr, Kralova H, Treska V, Radermacher P, and Novak I (2004) Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 21:458-465.
22. Picard S, Parthasarathy S, Fruebis J, and Witztum JL (1992) Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89:6876-6880.
23. Pleiner J, Mittermayer F, Schaller G, Marsik C, Macallister RJ, and Wolzt M (2003) Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol 42:1656-1662.
24. Razavi HM, Wang lF, Weicker S, Rohan M, Law C, McCormack DG, and Mehta S (2004) Pulmonary neutrophil infiltration in murine sepsis: role of inducible nitric oxide synthase. Am J Respir Crit Care Med 170:227-233.
25. Rosselet A, Feihl F, Markert M, Gnaegi A, Perret C, and Liaudet L (1998) Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 157:162-170.
26. Ruetten H, Southan GJ, Abate A, and Thiemermann C (1996) Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 118:261-270.
27. Schwartz D, Brasowski E, Raskin Y, Schwartz IF, Wolman Y, Blum M, Blantz RC, and Iaina A (2001) The outcome of non-selective vs selective nitric oxide synthase inhibition in lipopolysaccharide treated rats. J Nephrol 14:110-114.
28. Silva-Santos JE, Terluk MR, and Assreuy J (2002) Differential involvement of guanylate cyclase and potassium channels in nitric oxide-induced hyporesponsiveness to phenylephrine in endotoxemic rats. Shock 17:70-76.
29. Stanchina ML and Levy MM (2004) Vasoactive drug use in septic shock. Semin Respir Crit Care Med 25:673-681.
30. Strub A, Ulrich WR, Hesslinger C, Eltze M, Fuchss T, Strassner J, Strand S, Lehner M, and Boer R (2006) The novel imidazopyridine BYK191023 is a highly selective inhibitor of the inducible nitric-oxide synthase. Mol Pharmacol 69:328-337
31. Strunk V, Hahnenkamp K, Schneuing M, Fischer LG, and Rich GF (2001) Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation. Anesth Analg 92:681-687.
32. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, and Nathan CF (1991) Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci USA 88:7773-7777.
33. Titheradge MA (1999) Nitric oxide in septic shock. Biochim Biophys Acta 1411:437-455.
34. Tracey WR, Tse J, and Carter G (1995) Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric-oxide synthase inhibitors. J Pharmacol Exp Ther 272:1011-1015.
35. Tsuneyoshi I, Kanmura Y, and Yoshimura N (1996) Nitric oxide as a mediator of reduced arterial responsiveness in septic patients. Crit Care Med 24:1083-1086.
36. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, and Boyle WA 3rd (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487-493.
37. Wray GM, Millar CG, Hinds CJ, and Thiemermann C (1998) Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. Shock 9:329-335.
38. Wu CC, Chen SJ, Szabo C, Thiemermann C, and Vane JR (1995) Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 114:1666-1672.
39. 2 extraction capabilities during endotoxic shock. J Appl Physiol 83:1164-1173.